Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART
- Registration Number
- NCT05144386
- Lead Sponsor
- Excision BioTherapeutics
- Brief Summary
This is a First in Human (FIH) study of EBT-101 administered IV to aviremic HIV-1 infected adults on stable antiretroviral therapy (ART).
- Detailed Description
This is a FIH, open-label, sequential cohort, single ascending dose (SAD) study of EBT-101 administered IV to aviremic HIV-1 infected adults on stable ART.
...
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description EBT-101 Dose-Level 1 EBT-101 Cohort A: Participants will be administered dose-level 1 of EBT-101 EBT-101 Dose-Level 2 EBT-101 Cohort B: Participants will be administered dose-level 2 of EBT-101
- Primary Outcome Measures
Name Time Method Safety and Tolerability of EBT-101 48 weeks Safety and tolerability of EBT-101 will be assessed based on the incidence and severity of adverse events (AEs) according to Division of AIDS (DAIDS) 2017 over 48 weeks
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
Washington University
🇺🇸Saint Louis, Missouri, United States
Quest Clinical Research
🇺🇸San Francisco, California, United States
Cooper Health
🇺🇸Camden, New Jersey, United States
Related News
HIV/AIDS Awareness Month 2024: Looking Back at Progress in Gene Therapy and Gene Editing
Approximately 1.2 million people in the US live with HIV, 13% unaware. In 2022, 31,800 contracted HIV. Excision BioTherapeutics' EBT-101 CRISPR-based gene editing therapy met safety endpoints in a phase 1/2 trial, with one participant maintaining viral suppression for 16 weeks post-treatment. Novel gene editing approaches discussed at ASGCT 27th Annual Meeting include integrase-mediated programmable genomic integration and base editing for neurological disorders. AGT103-T gene therapy, blocking HIV-specific genes, showed promising efficacy signals in a phase 1 trial.
Future of CRISPR: Gene Editing Technologies Herald Landmark Clinical Trials
CRISPR technology, including CRISPR-Cas9, CRISPR-Cas12, and CRISPR-Cas13, is revolutionizing genome editing. FDA approved the first CRISPR-Cas9 drug, Casgevy®, for sickle cell disease and beta thalassemia. Other applications include treating urinary tract infections, hereditary transthyretin amyloidosis, hereditary angioedema, cardiovascular diseases, type 1 diabetes, systemic lupus erythematosus, HIV, and blood cancers. Challenges include cost, regulatory standards, and ethical considerations.
- Prev
- 1
- Next